Logo

Merck and Eisai’s Keytruda (pembrolizumab) + Lenvima (lenvatinib) Receive EC’s Approval as 1L Treatment of Advanced Renal Cell Carcinoma

Share this

Merck and Eisai’s Keytruda (pembrolizumab) + Lenvima (lenvatinib) Receive EC’s Approval as 1L Treatment of Advanced Renal Cell Carcinoma

Shots:

  • The approval is based on the P-III (CLEAR/KEYNOTE-581) study to evaluate Keytruda (200mg, IV, q3w for ~24mos.) + Lenvima (20mg, PO, qd) or Lenvima + everolimus vs sunitinib in a ratio (1:1:1) in 1069 patients with advanced RCC
  • The results showed an improvement in efficacy outcome measures of PFS & OS with the reduction in risk of disease progression or death (61% & 34%); m-PFS (23.9mos. vs 9.2mos.); m-OS was not reached; ORR (71% vs 36%), CR rate (16% vs 4%); PR rate (55% vs 32%)
  • The approval follows the marketing of Keytruda + Lenvima in 27 EU member states including Iceland, Liechtenstein, Norway & Northern Ireland. The combination therapy received the EC’s approval for 2 cancer i.e., advanced RCC & EC

 Ref: Businesswire | Image: Merck

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions